What is Wedbush's price target for FATE?

Wedbush's latest stated price target for Fate Therapeutics Inc. (FATE) is $7, from its action on Oct 27, 2025.

What is Wedbush's rating on FATE?

Wedbush rates FATE Outperform, a bullish rating, as of Oct 27, 2025.

When did Wedbush last change its view on FATE?

On Oct 27, 2025, Wedbush upgrades to Outperform from Neutral, price target $7.

Wedbush FATE price target and rating history

Fate Therapeutics Inc. (FATE) · Health Care

Wedbush rates Fate Therapeutics Inc. (FATE) Outperform with a $7 price target, as of its latest action on Oct 27, 2025. It has published 4 rating actions on FATE since December 2021, including 3 upgrades and 1 downgrade.

Current rating: Outperform
Price target: $7
Median target, all firms: Too few
Actions on FATE: 4

Wedbush price target on FATE

Wedbush price target on FATE, each point a stated target, December 2021 to October 2025.

Every Wedbush rating on FATE

Oct 27, 2025
UpgradeWedbush upgrades to Outperform from Neutral, price target $7
Jan 6, 2023
DowngradeWedbush downgrades to Neutral from Outperform, price target $42 to $7
Dec 15, 2021
UpgradeWedbush upgrades to Outperform from Neutral
Dec 15, 2021
UpgradeWedbush upgrades to Outperform from Neutral, price target $71 to $74

Questions about Wedbush and FATE

What is Wedbush's price target for FATE?: Wedbush's latest stated price target for Fate Therapeutics Inc. (FATE) is $7, from its action on Oct 27, 2025.
What is Wedbush's rating on FATE?: Wedbush rates FATE Outperform, a bullish rating, as of Oct 27, 2025.
When did Wedbush last change its view on FATE?: On Oct 27, 2025, Wedbush upgrades to Outperform from Neutral, price target $7.

More FATE rating histories

All Wedbush ratings FATE news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.